Mylan

What Mylan does

Mylan N.V., originally founded in 1961 as a generic pharmaceutical company, merged with Upjohn Inc. (a former division of Pfizer Inc.) in November 2020 to form Viatris Inc., a global healthcare company publicly traded on NASDAQ under the ticker VTRS. The combined entity operates as an integrated pharmaceutical platform focused on the manufacture, development, and distribution of generic and off-patent branded medicines, with operations spanning more than 165 countries and territories served through approximately 50 manufacturing facilities with an aggregate annual production capacity exceeding 80 billion units.

The company's core product offering is generic pharmaceuticals and medications distributed globally through two primary channels: traditional retail pharmacy distribution for prescription and over-the-counter medications serving end patients, and direct supply relationships with hospitals, clinics, and healthcare systems. Its technology stack is centered on pharmaceutical manufacturing processes and generic drug development rather than software or AI capabilities. The business operates on a sales-led go-to-market motion, monetizing through one-time prescription-based pharmaceutical sales with pricing not publicly disclosed.

Viatris serves two primary customer segments: end-use patients and healthcare consumers requiring access to affordable medications across geographies, and healthcare providers and pharmacies requiring reliable supply of quality medicines. The company's stated value proposition centers on ensuring access to high-quality, affordable medicines regardless of geography, underpinned by sustainable operations and innovative healthcare solutions, including global health initiatives such as HIV/AIDS treatment access programs supported through a network of 60+ partner organizations worldwide.

Name

Mylan

Legal name

Viatris Inc.

Website

https://mylan.pt

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Mylan, now operating as Viatris Inc. following its 2020 merger with Pfizer's Upjohn division, is a publicly traded global pharmaceutical company (NASDAQ: VTRS) that manufactures and distributes generic and off-patent branded medicines to patients, pharmacies, and healthcare providers across more than 165 countries and territories.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Specialty Pharmaceutical Distributors (HLAIAJAB), Hospital & Health-System Pharmaceutical Distributors (HLAIAJAD), Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Global healthcare access
• Prescription medications
• Infectious disease treatment

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Sales: Mylan generates revenue through the manufacture and sale of generic pharmaceuticals and medications. Following its merger with Upjohn to form Viatris, the combined entity operates with a focus on providing access to high-quality medicines globally.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Mylan, which merged with Upjohn (a Pfizer division) in November 2020 to form Viatris Inc., manufactures and sells generic pharmaceuticals and medications. The company operates approximately 50 manufacturing facilities globally, producing 80+ billion units annually, and distributes medicines across 165+ countries and territories through pharmacies and healthcare provider networks.

Product overview

Viatris is a single unified global healthcare company formed through the merger of Mylan and Upjohn. The company operates as one integrated platform offering pharmaceutical products and healthcare services, with manufacturing capabilities spanning approximately 50 factories worldwide and distribution across more than 165 countries and territories.

Differentiator

Problem solved

Functional benefit

Products and services

• Viatris (global healthcare company formed from Mylan and Upjohn merger)

Quantifiable outcome

• Access to medications across 165+ countries and territories

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Partner Organizations (60+ globally)coreOthersViatris leverages partnerships with 60+ organizations worldwide to connect people to pharmaceutical products and services. The partnership ecosystem includes collaborations for access to medicines, healthcare solutions, and global health initiatives including HIV/AIDS treatment programs.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sun Pharmaceutical Industries: India-headquartered global generic manufacturer with a broad specialty generics portfolio and large US presence. Direct competitor to Viatris in generic formulations and specialty generics.
• Apotex: Canada-headquartered global generic drug manufacturer. Comparable to Viatris in generic finished dosage forms and global distribution, particularly in North America and select international markets.
• Cipla: India-based global pharmaceutical company with strong generics and respiratory franchises. Direct competitor to Viatris, particularly in emerging markets and HIV/AIDS therapies.
• Sandoz (Novartis): Global generics and biosimilars business spun out of Novartis. Competes head-to-head with Viatris in generic small molecules and biosimilars across the same 165+ country footprint.
• Lupin Pharmaceuticals: India-headquartered global generic manufacturer with significant US generics business. Competes with Viatris in oral solids, injectables, and specialty respiratory generics.
• Aurobindo Pharma: Large Indian generic manufacturer with a wide product portfolio and significant US and EU generics business. Directly competes with Viatris on price and scale across multiple molecules.
• Teva Pharmaceutical Industries: Largest global generic drug manufacturer with a broad specialty and generics portfolio. Direct peer to Viatris across both generic and off-patent branded segments, with comparable global distribution and manufacturing scale.
• Amneal Pharmaceuticals: US-based generic and specialty pharmaceutical manufacturer with a broad generics portfolio, injectables, and biosimilars pipeline. Directly competes with Viatris across US generic channels.
• Hikma Pharmaceuticals: Jordan-headquartered global generic and specialty pharmaceutical company with strong US injectables and generics franchises. Comparable to Viatris in generic and injectable products across multiple geographies.
• Dr. Reddy's Laboratories: India-based global generics and biosimilars company with strong US presence. Comparable to Viatris in generic small molecules, complex generics, and biosimilars.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/viatrisinc
• YouTubeyoutube.com/viatris
• LinkedInlinkedin.com/company/laborat-rios-delta
• Instagraminstagram.com/viatrisinc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mylan